DRR168523
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.450
- NOTCH_SIGNALING+0.360
- WNT_BETA_CATENIN_SIGNALING+0.250
- PEROXISOME+0.230
- MYC_TARGETS_V1+0.220
- TGF_BETA_SIGNALING+0.210
- OXIDATIVE_PHOSPHORYLATION+0.180
- P53_PATHWAY+0.160
- ADIPOGENESIS+0.130
- FATTY_ACID_METABOLISM+0.130
Top 10 suppressed
- INFLAMMATORY_RESPONSE-0.550
- ALLOGRAFT_REJECTION-0.540
- INTERFERON_ALPHA_RESPONSE-0.530
- INTERFERON_GAMMA_RESPONSE-0.520
- IL6_JAK_STAT3_SIGNALING-0.450
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.410
- COMPLEMENT-0.380
- IL2_STAT5_SIGNALING-0.370
- KRAS_SIGNALING_UP-0.360
- ANGIOGENESIS-0.350
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-B6-A0X0-01A-21R-A115-07 | — | B | 0.836 |
| 2 | SRR12475154 | — | — | 0.819 |
| 3 | 5cfccf66-7f7d-4385-96c8-8628a3cdbecb | — | — | 0.815 |
| 4 | TCGA-34-2600-01A-01R-0851-07 | — | cohortSQ1 | 0.806 |
| 5 | MDT-AP-0360 | Med | Medulloblastoma | 0.805 |
| 6 | R230 | — | — | 0.805 |
| 7 | R45 | — | — | 0.803 |
| 8 | a7d1fe23-5255-4daa-a6a9-fe2f67491323 | — | — | 0.802 |
| 9 | SRR6013506 | — | cohortA2 | 0.799 |
| 10 | SRR4296082 | — | cohortA1 | 0.796 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.450 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.360 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.250 | Inavolisib | — uncovered |
| PEROXISOME | 0.230 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.220 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.210 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.180 | Remibrutinib | — uncovered |
| P53_PATHWAY | 0.160 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.130 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.130 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.110 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.080 | Temsirolimus | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.080 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.080 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.080 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.070 | Remibrutinib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.060 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.060 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.030 | Temsirolimus | — uncovered |
| MYOGENESIS | 0.030 | Inavolisib | — uncovered |